

Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications

Stockholm, 18 June 2026 — Modus Therapeutics Holding AB (publ) (Nasdaq First North Growth Market: MODTX) announces that Professor Kathryn Maitland and her research group at Imperial College London have submitted a manuscript based on the Phase Ib study SEVUSMART for publication in the journal *Nature Communications*. The manuscript is available as a preprint via Research Square.

SEVUSMART is a Phase Ib study evaluating sevuparin as an adjunctive treatment for severe malaria in children. The study is conducted as an investigator-led study with Imperial College London as sponsor and Professor Maitland as principal investigator, funded by a research grant from the Wellcome Trust. Modus Therapeutics contributed sevuparin as well as scientific and regulatory expertise, and holds the commercial rights to the drug candidate.

“The submission of the SEVUSMART manuscript is an important step in the ongoing work to document sevuparin’s clinical profile in severe malaria. Pending peer review, we can note that the study has clearly defined the dose for the next study and confirms sevuparin’s favorable safety and tolerability profile,” says John Öhd, CEO of Modus Therapeutics. “We welcome Professor Maitland’s research group sharing their findings with the scientific community and look forward to the continued work to identify the next steps in program development.”

The manuscript posted on Research Square can be found here: [Sevuparin in children with severe malaria: A phase I safety and dose finding trial | Research Square](#)

About SEVUSMART

SEVUSMART (ISRCTN number: [ISRCTN32271864](#)) is a Phase Ib study evaluating the dosing and tolerability/safety of sevuparin in combination with standard of care for severe malaria in up to 20 pediatric patients aged 3 months to 12 years. The study was conducted at research centers in Kenya and Zambia and completed patient recruitment in March 2025. Imperial College London is the sponsor; the study has been funded by the Wellcome Trust.

For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

This information is information that Modus Therapeutics Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-06-18 18:10 CEST.

Certified Adviser

Bergs Securities AB

Hemsida: www.bergssecurities.se

About Modus Therapeutics and sevuparin

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments

Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications